Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
about
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungsThe combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosisA virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhATowards a new tuberculosis drug: pyridomycin - nature's isoniazidTime-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo EfficacyTB drug development: immunology at the tablePhosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosisCombining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug DiscoveryDiscovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014-2015).The mycobacterial cell envelope-lipidsBiological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosisBayesian models leveraging bioactivity and cytotoxicity information for drug discovery.Polymorphisms in isoniazid and prothionamide resistance genes of the Mycobacterium tuberculosis complex.Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs.Structure of Ribosomal Silencing Factor Bound to Mycobacterium tuberculosis RibosomeSynthesis and biological activity of alkynoic acids derivatives against mycobacteriaAntitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Nitrite impacts the survival of Mycobacterium tuberculosis in response to isoniazid and hydrogen peroxide.Targeting the mycobacterial envelope for tuberculosis drug development.Advances In Mycobacterium Tuberculosis Therapeutics Discovery Utlizing Structural Biology.Resistance in tuberculosis: what do we know and where can we go?Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Targeting Phenotypically Tolerant Mycobacterium tuberculosis.Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery.Addressing the Metabolic Stability of Antituberculars through Machine Learning.Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.Novel Pyrimidines as Antitubercular Agents.
P2860
Q21089606-077BEFAB-C7FF-49FD-A0EA-6CFBB093F27CQ24633894-9E73EFEE-CC25-4DCC-958C-0A5AB4C1348EQ27339306-62A39EAE-7D16-4836-85ED-F805F9A128AFQ27673316-95669248-3686-4EF7-B830-18762D2B95B1Q27682088-BBD02882-A458-43A4-98BF-6FA593E69C02Q28083600-C56DF31C-4F89-4468-8240-1913330734B9Q28538596-2BAFA524-77A0-4673-A5BF-31D76F8B69CCQ28550561-C415DB5A-6509-4CA3-8F84-619A84D4E30EQ30396236-6C478E60-7E94-4D9E-8D67-DF48FD3939C0Q30432374-58BA84CD-50F2-4019-B287-B58B0907FDA5Q31110187-BB195572-78D3-4FA8-AED0-1A6D85077AB1Q34355375-007C2C1E-C815-4430-BA5B-D0786F663521Q34421869-1A34E5F7-00C8-4D7E-9381-AB32110274D6Q34632430-13440C15-2F38-4D16-B3FC-B729C1ADC7ACQ35191465-134FF785-9CEE-4F61-9EE8-08EF61608734Q35923699-01B16599-7E5A-477E-8054-9C07563A0747Q36167169-7A7CCF8A-17B2-4C03-924D-58D3B6178831Q36256916-ADC42E39-D330-45FE-B255-EBD87651FD92Q36478960-DD87ED52-2058-4D7C-B624-FF664201CA9BQ36480015-EC1E1B68-FFBB-41EE-A560-795EC6105A93Q37034701-0DCA8C7A-FD6E-4D71-A400-ACC02DC1431AQ37403156-A46427B3-1C41-4B15-9786-03F4346BDDE0Q37480947-F4F3B45C-396C-40FB-986B-9DECC73DC972Q38056149-D0233898-12FF-4CBC-BBEA-73AF36946FC9Q38061197-F9FC4DEB-94F4-45A9-9E08-C76497A8C33BQ38124261-5C6AB63A-43AE-48C6-8E30-5F681C9BAD87Q38266496-BFA0041E-2C5D-4404-B0F5-7D042B571E7DQ38782638-18EC4AF6-4897-4209-9F74-3DBCD6F7C7EDQ39149038-E3B983B5-7217-40BC-BB69-36F756D6DBE3Q39378972-81F366EE-528F-4560-B8B7-B7834DE4C09CQ45944729-E417641A-221A-4C67-A645-034EF5873F65Q46070584-CD6C63FA-BA7D-4340-928A-9C27292EADCCQ50134166-2ABB84A8-BB9F-4A37-B974-09BDAF4A9CB6
P2860
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@ast
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@en
type
label
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@ast
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@en
prefLabel
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@ast
Novel inhibitors of InhA effic ...... obic and anaerobic conditions.
@en
P2093
P2860
P50
P356
P1476
Novel inhibitors of InhA effic ...... robic and anaerobic conditions
@en
P2093
Catherine Vilchèze
David Alland
James C Sacchettini
JoAnn Tufariello
Joel S Freundlich
P2860
P304
P356
10.1128/AAC.00266-11
P407
P577
2011-05-31T00:00:00Z